| Issue Date | Title | Author(s) |
| Sep-2023 | Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database | Liu, Xin; Zhang, Li-Ling; Qu, Bao-Lin; Zhong, Qiu-Zi; Qian, Li-Ting; Yang, Yong; Hou, Xiao-Rong; Qiao, Xue-Ying; Wang, Hua; Zhu, Yuan; Cao, Jian-Zhong; Wu, Jun-Xin; Wu, Tao; Zhu, Su-Yu; Shi, Mei; Zhang, Hui-Lai; Zhang, Xi-Mei; Su, Hang; Song, Yu-Qin; Zhu, Jun; Zhang, Yu-Jing; Huang, Hui-Qiang; Wang, Ying; Chen, Fan; Yin, Lin; He, Xia; Cai, Shang; Li, Ye-Xiong; Qi, Shu-Nan |
| 14-Jul-2020 | First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG | Qi, Shu-Nan; Yang, Yong; Song, Yu-Qin; Wang, Ying; He, Xia; Hu, Chen; Zhang, Li-Ling; Wu, Gang; Qu, Bao-Lin; Qian, Li-Ting; Hou, Xiao-Rong; Zhang, Fu-Quan; Qiao, Xue-Ying; Wang, Hua; Li, Gao-Feng; Huang, Hui-Qiang; Zhang, Yu-Jing; Zhu, Yuan; Cao, Jian-Zhong; Wu, Jun-Xin; Wu, Tao; Zhu, Su-Yu; Shi, Mei; Xu, Li-Ming; Yuan, Zhi-Yong; Su, Hang; Zhu, Jun; Li, Ye-Xiong |
| Apr-2024 | Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma | Song, Yu-Qin; Zhang, Hui-Lai; Huang, Hui-Qiang; Zhang, Qing-Yuan; Jing, Hong -Mei; Wang, Chao; Wu, Chun; Li, Dong-Hang; Dai, Yu; Humphrey, Kathryn; Zhu, Jun |
| 2024 | Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma | Luo, Fei; Zhong, Qiu-Zi; Liu, Xin; Hou, Xiao-Rong; Qian, Li-Ting; Qiao, Xue-Ying; Wang, Hua; Zhu, Yuan; Cao, Jian-Zhong; Wu, Jun-Xin; Wu, Tao; Zhu, Su-Yu; Shi, Mei; Zhang, Hui-Lai; Zhang, Xi-Mei; Su, Hang; Song, Yu-Qin; Zhu, Jun; Zhang, Yu-Jing; Huang, Hui-Qiang; Wang, Ying; He, Xia; Zhang, Li-Ling; Qu, Bao-Lin; Yang, Yong; Hu, Chen; Deng, Min; Wang, Shu-Lian; Qi, Shu-Nan; Li, Ye-Xiong |
| 2013 | Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma | Shi, Yuan-Kai; Dong, Mei; Hong, Xiao-Nan; Zhang, Wei-Jing; Feng, Ji-Feng; Zhu, Jun; Yu, Li; Ke, Xiao-Yan; Huang, Hui-Qiang; Shen, Zhi-Xiang; Fan, Yun; Li, Wei; Zhao, Xie-Lan; Qiu, Lu-Gui; Huang, He |
| Jun-2021 | Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Yang, Yong; Wang, Ying; Liu, Xin; He, Xia; Zhang, Li-Ling; Wu, Gang; Qu, Bao-Lin; Qian, Li-Ting; Hou, Xiao-Rong; Zhang, Fu-Quan; Qiao, Xue-Ying; Wang, Hua; Li, Gao-Feng; Zhu, Yuan; Cao, Jian-Zhong; Wu, Jun-Xin; Wu, Tao; Zhu, Su-Yu; Shi, Mei; Xu, Li-Ming; Su, Hang; Song, Yu-Qin; Zhu, Jun; Zhang, Yu-Jing; Huang, Hui-Qiang; Hu, Chen; Qi, Shu-Nan; Li, Ye-Xiong |
| Sep-2020 | Risk-based, response-adapted therapy for early-stage extranodal nasal-typeNK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study | Qi, Shu-Nan; Yang, Yong; Zhang, Yu-Jing; Huang, Hui-Qiang; Wang, Ying; He, Xia; Zhang, Li-Ling; Wu, Gang; Qu, Bao-Lin; Qian, Li-Ting; Hou, Xiao-Rong; Zhang, Fu-Quan; Qiao, Xue-Ying; Wang, Hua; Li, Gao-Feng; Zhu, Yuan; Cao, Jian-Zhong; Wu, Jun-Xin; Wu, Tao; Zhu, Su-Yu; Shi, Mei; Xu, Li-Ming; Yuan, Zhi-Yong; Su, Hang; Song, Yu-Qin; Zhu, Jun; Hu, Chen; Li, Ye-Xiong |
